Articles: human.
-
Objective : Disabled-2 (Dab2) is an important endocytic adaptor which plays an inhibition role in cancer cell growth. The objective of this study was to systematically review expressions of Dab2 in human cancers. Methods : Eligible studies about Dab2 in human cancers were retrieved from databases of PubMed, Embase, Web of Science. ⋯ The results indicated loss expressions of Dab2 were observed in 74.9% and 46.9% in human malignant cancer tissues and cancer cell lines, respectively. The ratio of Dab2 promotor hypermethylation is 34.54% in cancer tissues which Dab2 expression are lost, but none in the control tissues or cells by Methylation-specific PCR (MSP). Conclusions : The expressions of Dab2 are frequently lost in human malignant cancer tissues, and promotor hypermethylation of Dab2 are common in human malignant cancer tissues, which is an important factor for the loss expression of Dab2 in human cancers tissues.
-
Asthma PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Galectins are a family of b-galactoside-binding animal lectins with functions in a variety of biological processes, including inflammation and allergic pathologies. To explore the contribution of galectins in human asthma, induced sputum samples were collected from asthma patients and healthy controls. Expression of galectin (gal)-1, gal-3 and gal-9 was analysed by flow cytometry. ⋯ The following authors have nothing to disclose: Silvia Sanchez, Rosa Girón Moreno, Rosa Gomez Punter, Emma Vazquez, Gonzalo Segrelles, Carolina Cisneros, Julio Ancochea BermúdezNo Product/Research Disclosure Information.
-
Transplantation PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: We developed a protocol to procure human lungs from victims of cardiac arrest in an urban county in North Carolina by co-operation with Emergency Medical Services (EMS), our organ procurement organization (OPO), and our hospital, and evaluate them for transplant suitability with EVLP (XVIVO™). ⋯ Thomas Egan: Other: Received donations-in-kind (equipment and supplies) from XVIVO for this research, Shareholder: and Founder, X-In8 Biologicals Corporation, deveoping products to reduce ischemia-reperfusion injury for transplant. My spouse is paid hourly for bookkeeping of NIH-funded grants., Fiduciary position (of any organization, association, society, etc, other than ACCP: President and founder of Lung Banks of America, a 501(c)3 Corporation whose mission is to promote lung retrieval from non-heart-beating donors. I am not paid. My spouse will be paid to administer a subcontract on a NIH-funded subcontract as Sect-Treasurer., Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary John Blackwell: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Lolita Forrest: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary William Simmons: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Katherine Birchard: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary William Funkhouser: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Boming Dong: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project, Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Staci Beamer: Other: My PI and my Department received donations-in-kind (equipment and supplies) from XVIVO for this project Sheakar Reddy: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary Nissa Casey: Grant monies (from sources other than industry): This work was supported by NIH grant 1RC2HL101641-01, which paid part of my salary The following authors have nothing to disclose: J Brent Meyers, Michael Bachman, Ginger Delario, Danielle NiedfeldtEx-vivo lung perfusion (EVLP) is not approved by the FDA in humans for transplant. EVLP of lungs retrieved after death is also not approved for use in humans. The presenter has an IDE from the FDA and UNC IRB approval to offer suitable lungs retrieved after death assessed by EVLP for transplant to consented patients.
-
Infectious Disease Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: The Milwaukee Protocol was used for a 24 year-old male U.S. soldier who was diagnosed with rabies after being bit by a feral dog in Afghanistan. He did not receive effective post exposure prophylaxis (PEP) for rabies however [1]. ⋯ Our case highlights the first time ECMO was used in rabies. Also, it exemplifies another failed case of the Milwaukee Protocol. Given the lack of efficacy, the protocol should not be used for rabies. A better understanding of rabies pathogenesis is needed in order to develop novel therapies.Reference #1: Jackson AC. Current and future approaches to the therapy of human rabies. Antiviral Res. 2013 Jul;99(1):61-7.Reference #2: Willoughby,R et. Al Survival after Treatment of Rabies with Induction of Coma, N Engl J Med2005; 352:2508-2514DISCLOSURE: The following authors have nothing to disclose: Amritpal Nat, Amitpal Nat, Amit Sharma, Aravind Pothineni, Ioana AmzutaNo Product/Research Disclosure Information.
-
Telemedicine PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To describe the telenursing protocol developed to improving pulmonary function in patients with heart failure (HF) in a developing country. ⋯ The following authors have nothing to disclose: Carolina Santos, Bárbara Sueli Moreira, Loyane Alves, Fernanda Mussi, Carolina Souza-MachadoNo Product/Research Disclosure Information.